70 Biggest Movers From Friday

Gainers

• GTY Technology Holdings Inc. GTYH shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners.
• Vaxxinity, Inc. VAXX jumped 84.2% to close at $6.95. Vaxxinity Executive chairman Lou Reese purchased 22,912 shares at $3.48 per share.
• Belite Bio Inc. ADR BLTE shares jumped 76.5% to close at $10.59 on Friday. Belite Bio priced its 6 million ADS IPO at $6 per ADS.
• Redbox Entertainment Inc. RDBX climbed 69.4% to close at $5.98.
• Cyngn Inc. CYN climbed 40.5% to close at $5.52. Cyngn priced its 6.45 million share offering at $3.10 per unit.
• Marrone Bio Innovations, Inc. MBII jumped 30.6% to settle at $1.16.
• Skylight Health Group Inc. SLHG gained 25.3% to close at $0.94. Skylight Health issued a clinical research update.
• Leju Holdings Limited LEJU surged 25% to close at $0.4749.
• Zymeworks Inc. ZYME shares gained 23.2% to close at $6.95. Zymeworks confirmed it received an unsolicited, non-binding proposal from All Blue Falcons FZE and its affiliates to purchase the company for $10.50 per share. The Zymeworks board of directors will carefully review the proposal.
• Alaunos Therapeutics, Inc. TCRT surged 22.6% to close at $0.5314.
• 180 Life Sciences Corp. ATNF rose 22.5% to settle at $2.12.
• Bioceres Crop Solutions Corp. BIOX jumped 22% to close at $14.60. China approved the HB4 strain of soy developed by Bioceres.
• Full Truck Alliance Co. Ltd. YMM rose 20.6% to close at $6.03 on hopes Chinese regulators will ease its crackdown on tech and internet companies.
• Clearwater Paper Corporation CLW rose 20.6% to close at $33.11 after the company reported better-than-expected Q1 EPS and sales results.
• Finch Therapeutics Group, Inc. FNCH rose 20.5% to close at $2.53. The FDA has removed the clinical hold on Finch Therapeutics Group’s investigational new drug application for CP101, an orally administered microbiome therapeutic, which is in Phase 3 study for recurrent C. difficile infection.
• Puyi Inc. PUYI gained 20.2% to close at $5.20.
• Anixa Biosciences, Inc. ANIX climbed 19.5% to close at $3.25.
• 17 Education & Technology Group Inc. YQ surged 18.5% to settle at $2.37
• Hello Group Inc. MOMO gained 17.4% to close at $5.32.
• Nutex Health, Inc. NUTX jumped 15.7% to close at $9.42.
• China Liberal Education Holdings Limited CLEU gained 14.7% to settle at $1.48.
• Pinduoduo Inc. PDD rose 13.5% to close at $43.09 after a Chinese state media report indicated the Chinese government may end its regulatory crackdown on big tech firms.
• Fangdd Network Group Ltd. DUO gained 13.1% to close at $0.28
• Kanzhun Limited BZ climbed 12.9% to close at $23.53.
• Cytokinetics, Incorporated CYTK climbed 11.5% to close at $39.87. HC Wainwright & Co. maintained Cytokinetics with a Buy and raised the price target from $69 to $75.
• NCR Corporation NCR gained 9.9% to close at $35.03.
• Bilibili Inc. BILI rose 9.7% to close at $24.34 on hopes Chinese regulators will ease its crackdown on tech and internet companies.
• ATRenew Inc. RERE rose 8.4% to close at $2.84.
• Opiant Pharmaceuticals, Inc. OPNT gained 8.4% to close at $19.96. Opiant Pharmaceuticals and Hikma Earlier reported exclusive $225 million commercialization and license agreement for OPNT003, Nasal Nalmefene, in Europe and UK.
• Alibaba Group Holding Limited BABA rose 6.8% to close at $97.09. Analysts slashed the earnings estimates for the Chinese technology giants for a second straight month amid the nation’s persistent goal of its Covid-Zero strategy, Bloomberg reported. Analysts trimmed Alibaba Group estimates by 4.2%.
• JD.com, Inc. JD gained 6.7% to close at $61.66 after a Chinese state media report indicated the Chinese government may end its regulatory crackdown on big tech firms.
• iQIYI, Inc. IQ shares gained 6.6% to settle at $3.56 on hopes Chinese regulators will ease its crackdown on tech and internet companies.
• KE Holdings Inc. BEKE gained 6.5% to close at $14.18.
• Innate Pharma S.A. IPHA rose 6.3% to close at $61.66. Innate Pharma announced that AstraZeneca has started dosing in its Phase 3 trial, PACIFIC-9, evaluating durvalumab (PD-L1) combined with monalizumab (NKG2A) or AstraZeneca's oleclumab (anti-CD73) in non-small cell lung cancer.
• Trip.com Group Limited TCOM jumped 6.1% to settle at $23.65.
• GDS Holdings Limited GDS rose 6% to close at $31.42. GDS Holdings filed its annual report on Form 20-F for the fiscal year ended December 31, 2021.

Losers

• Accolade, Inc. ACCD shares dipped 49.7% to close at $5.56 on Friday after the company reported Q4 earnings results and issued Q1 sales guidance below analyst estimates.
• Genocea Biosciences, Inc. GNCA declined 30.5% to close at $0.2833 after the company announced that it has initiated a process to explore a range of strategic alternatives including the sale of all or part of the company, a merger or a reverse merger.
• Missfresh Limited MF dropped 27.7% to close at $0.5160.
• LianBio LIAN fell 23.7% to settle at $3.83. LianBio highlighted that its partner, Bristol Myers, announced the FDA approval for Camzyos.
• Vivakor, Inc. VIVK dropped 23.4% to close at $2.58.
• Cooper-Standard Holdings Inc. CPS fell 22.5% to close at $4.61.
• CooTek (Cayman) Inc. CTK fell 22.4% to close at $0.1701 after the company announced a plan to implement a 1-to-650 ADS ratio change.
• Veritone, Inc. VERI dipped 21.7% to close at $10.83.
• IRadimed Corporation IRMD dropped 20.1% to settle at $32.91 after the company reported Q1 financial results and issued FY22 guidance.
• Ostin Technology Group Co., Ltd. OST fell 19.6% to close at $3.70 following recent IPO.
• Cloopen Group Holding Limited RAAS dipped 18.8% to settle at $0.7390.
• Venus Concept Inc. VERO dropped 17.4% to close at $0.8340. Venus Concept recently received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Venus BlissMAX device with an expanded indication for use in new areas of the body and an increase in RF energy output.
• Sono Group N.V. SEV fell 17.2% to close at $3.95.
• IES Holdings, Inc. IESC dipped 17.1% to close at $29.30 after the company posted a loss for its second quarter.
• Vigil Neuroscience, Inc. VIGL fell 16.9% to close at $3.39.
• Aldeyra Therapeutics, Inc. ALDX fell 15.9% to settle at $3.07. Aldeyra Therapeutics CFO and Treasurer Joshua Reed tendered his resignation to pursue other career opportunities.
• B. Riley Financial, Inc. RILY declined 15.8% to close at $45.16 following Q1 results.
• Clarus Therapeutics Holdings, Inc. CRXT dropped 15.5% to settle at $0.6255.
• Imago BioSciences, Inc. IMGO fell 15% to close at $16.35.
• Swvl Holdings Corp. SWVL dipped 14.9% to settle at $8.59
• Studio City International Holdings Limited MSC fell 14.4% to close at $3.81.
• VeriSign, Inc. VRSN fell 14.3% to close at $178.69 following Q1 results.
• Mitek Systems, Inc. MITK fell 14.1% to close at $11.17 following Q2 results.
• Amazon.com, Inc. AMZN shares fell 14.1% to close at $2,485.63. Amazon reported a $3.8 billion net loss for the first quarter, versus a year-ago net income of $8.1 billion. The company also issued weak Q2 sales guidance.
• Color Star Technology Co., Ltd. CSCW dropped 13.6% to settle at $0.1555.
• Atlassian Corporation Plc TEAM fell 13.5% to close at $224.83.
• Loyalty Ventures Inc. LYLT dropped 13.5% to close at $12.79.
• Century Aluminum Company CENX fell 12.7% to settle at $16.87 after reporting Q1 results.
• The Western Union Company WU fell 12.6% to close at $16.76 after the company reported worse-than-expected Q1 sales results and cut guidance.
• T Stamp Inc. IDAI fell 12.3% to close at $4.12. T Stamp shares jumped around 124% on Thursday after the company announced the launch of its Biometric MFA solution.
• Statera Biopharma, Inc. STAB shares dipped 12% to close at $0.3345. Statera Biopharma shares jumped over 80% on Thursday after the company and Immune Therapeutics announced a strategic agreement for rights to low dose naltrexone.
• Ra Medical Systems, Inc. RMED fell 11.5% to close at $0.33 after jumping 26% on Thursday.
• AbbVie Inc. ABBV fell 6.1% to close at $146.88 after the company reported worse-than-expected Q1 sales results and updated guidance.
• Evoke Pharma, Inc. EVOK shares fell 5.6% to close at $0.47 after dipping 25% on Thursday.